Pathological mechanisms in progressive multiple sclerosis

The Lancet Neurology

Volumn 14, Issue 2, 2015, Pages 183-193

  Mahad, Don H ^a   Trapp, Bruce D ^b   Lassmann, Hans ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; AUTACOID;

AGE; AGING; ARTICLE; CELL ACTIVATION; CELL HYPOXIA; CELL STRESS; DEMYELINATING DISEASE; DEMYELINATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HOMEOSTASIS; HUMAN; INFLAMMATION; MICROGLIA; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY BURST; TISSUE INJURY; ANIMAL; BRAIN; METABOLISM; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; INFLAMMATION MEDIATORS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NERVE DEGENERATION; RESPIRATORY BURST;

EID: 84922485376     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70256-X     Document Type: Review

References (117)

1. Lassmann H, Brück W, Lucchinetti CF The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
2. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911. the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
3. Marburg O Die sogenannte "akute Multiple Sklerose". Jahrb Psychiatrie 1906, 27:211-312. (in German).
4. Wiendl H, Hohlfeld R Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009, 72:1008-1015.
5. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012, 248:87-103.
6. Ascherio A, Munger KL Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007, 61:288-299.
7. Hohlfeld R, Wekerle H Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004, 101(suppl 2):14599-14606.
8. Coles AJ Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 2013, 10:29-33.
9. Trapp BD, Nave KA Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
10. Schuh C, Wimmer I, Hametner S, et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol 2014, 128:247-266.
11. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. the International Multiple Sclerosis Genetics Consortium, the Wellcome Trust Case Control Consortium 2the Wellcome Trust Case Control Consortium 2.
12. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
13. Obermeier B, Lovato L, Mentele R, et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 2011, 233:245-248.
14. Skulina C, Schmidt S, Dornmair K, et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004, 101:2428-2433.
15. Fischer MT, Wimmer I, Hoftberger R, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013, 136:1799-1815.
16. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135:886-899.
17. Smith AM, Dragunow M The human side of microglia. Trends Neurosci 2014, 37:125-135.
18. Mahad D, Ziabreva I, Lassmann H, Turnbull D Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008, 131:1722-1735.
19. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011, 69:481-492.
20. Davies AL, Desai RA, Bloomfield PS, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol 2013, 74:815-825.
21. Brownell B, Hughes JT The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962, 25:315-320.
22. Holland CM, Charil A, Csapo I, et al. The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging 2012, 22:129-136.
23. Hallgren B, Sourander P The effect of age on the non-haemin iron in the human brain. J Neurochem 1958, 3:41-51.
24. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013, 74:848-861.
25. Lansley J, Mataix-Cols D, Grau M, Radua J, Sastre-Garriga J Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev 2013, 37:819-830.
26. Mycko MP, Brosnan CF, Raine CS, Fendler W, Selmaj KW Transcriptional profiling of microdissected areas of active multiple sclerosis lesions reveals activation of heat shock protein genes. J Neurosci Res 2012, 90:1941-1948.
27. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003, 13:554-573.
28. Cunnea P, Mháille AN, McQuaid S, Farrell M, McMahon J, FitzGerald U Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. Mult Scler 2011, 17:808-818.
29. Stys PK General mechanisms of axonal damage and its prevention. J Neurol Sci 2005, 233:3-13.
30. Vergo S, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011, 134:571-584.
31. di Nuzzo L, Orlando R, Nasca C, Nicoletti F Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther 2014, 8:555-568.
32. de Vries HE, Witte M, Hondius D, et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?. Free Radic Biol Med 2008, 45:1375-1383.
33. Waxman SG Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 2008, 4:159-169.
34. Bermel RA, Bakshi R The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006, 5:158-170.
35. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
36. Ferguson B, Matyszak MK, Esiri MM, Perry VH Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
37. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
38. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000, 48:893-901.
39. Bjartmar C, Wujek JR, Trapp BD Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003, 206:165-171.
40. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000, 157:267-276.
41. Wujek JR, Bjartmar C, Richer E, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002, 61:23-32.
42. Mews I, Bergmann M, Bunkowski S, Gullotta F, Brück W Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998, 4:55-62.
43. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50:389-400.
44. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009, 66:1144-1150.
45. Nielsen AS, Kinkel RP, Madigan N, Tinelli E, Benner T, Mainero C Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology 2013, 81:641-649.
46. Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol 2012, 72:918-926.
47. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011, 365:2188-2197.
48. Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003, 62:723-732.
49. Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: Similarities and differences. Neurology 2008, 70:336-343.
50. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135:2925-2937.
51. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
52. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006, 67:960-967.
53. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007, 17:38-44.
54. Geurts JJ, Bö L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007, 66:819-827.
55. Vercellino M, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009, 68:489-502.
56. Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 2011, 69:445-454.
57. Dutta R, Chomyk AM, Chang A, et al. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol 2013, 73:637-645.
58. Evangelou N, DeLuca GC, Owens T, Esiri MM Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 2005, 128:29-34.
59. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003, 60:1157-1162.
60. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010, 68:465-476.
61. Huynh JL, Garg P, Thin TH, et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci 2014, 17:121-130.
62. Franklin RJ, Ffrench-Constant C Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008, 9:839-855.
63. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
64. Albert M, Antel J, Brück W, Stadelmann C Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 2007, 17:129-138.
65. Bramow S, Frischer JM, Lassmann H, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010, 133:2983-2998.
66. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES Multiple sclerosis. pathology of recurrent lesions. Brain 1993, 116:681-693.
67. Rodgers JM, Robinson AP, Miller SD Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis. Discov Med 2013, 16:53-63.
68. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998, 8:681-694.
69. Merkler D, Ernsting T, Kerschensteiner M, Bruck W, Stadelmann C A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 2006, 129:1972-1983.
70. Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005, 128:2713-2721.
71. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013, 45:1353-1360. the International Multiple Sclerosis Genetics Consortium (IMSGC), the Wellcome Trust Case Control Consortium 2 (WTCCC2)the Wellcome Trust Case Control Consortium 2 (WTCCC2), the International IBD Genetics Consortium (IIBDGC)the International IBD Genetics Consortium (IIBDGC).
72. Hochmeister S, Grundtner R, Bauer J, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006, 65:855-865.
73. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
74. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
75. Meinl E, Krumbholz M, Hohlfeld R B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006, 59:880-892.
76. Engelhardt B, Ransohoff RM The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005, 26:485-495.
77. Ransohoff RM, Liu L, Cardona AE Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol 2007, 82:187-204.
78. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003, 126:1048-1057.
79. Na SY, Cao Y, Toben C, et al. Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 2008, 131:2353-2365.
80. Saxena A, Bauer J, Scheikl T, et al. Cutting edge: Multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J Immunol 2008, 181:1617-1621.
81. Linington C, Bradl M, Lassmann H, Brunner C, Vass K Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130:443-454.
82. Felts PA, Woolston AM, Fernando HB, et al. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 2005, 128:1649-1666.
83. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
84. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001, 50:646-657.
85. Gray E, Thomas TL, Betmouni S, Scolding N, Love S Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 2008, 444:195-198.
86. Czeh M, Gressens P, Kaindl AM The yin and yang of microglia. Dev Neurosci 2011, 33:199-209.
87. Vogel DY, Vereyken EJ, Glim JE, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 2013, 10:35.
88. Perry VH, Nicoll JA, Holmes C Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193-201.
89. Kolasinski J, Stagg CJ, Chance SA, et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain 2012, 135:2938-2951.
90. Ohno N, Kidd GJ, Mahad D, et al. Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier. J Neurosci 2011, 31:7249-7258.
91. Larsson NG Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem 2010, 79:683-706.
92. Ohno N, Chiang H, Mahad DJ, et al. Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons. Proc Natl Acad Sci USA 2014, 111:9953-9958.
93. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132:1161-1174.
94. Witte ME, Bø L, Rodenburg RJ, et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009, 219:193-204.
95. Kiryu-Seo S, Ohno N, Kidd GJ, Komuro H, Trapp BD Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport. J Neurosci 2010, 30:6658-6666.
96. Andrews H, White K, Thomson C, et al. Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse. J Neurosci Res 2006, 83:1533-1539.
97. Zambonin JL, Zhao C, Ohno N, et al. Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain 2011, 134:1901-1913.
98. Kang JS, Tian JH, Pan PY, et al. Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell 2008, 132:137-148.
99. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006, 59:478-489.
100. Witte ME, Nijland PG, Drexhage JA, et al. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013, 125:231-243.
101. Hares K, Kemp K, Rice C, Gray E, Scolding N, Wilkins A Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis. Mult Scler 2013, published online Oct 21. http://dx.doi.org/10.1177/1352458513508836.
102. Harris H, Rubinsztein DC Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 2012, 8:108-117.
103. Stromillo ML, Giorgio A, Rossi F, et al. Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology 2013, 80:2090-2094.
104. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001, 248:979-986. the Arnason BGW.
105. Murphy MP How mitochondria produce reactive oxygen species. Biochem J 2009, 417:1-13.
106. Trapp BD, Stys PK Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009, 8:280-291.
107. Connor J Iron and glia. Neuroglia 2013, 586-602. Oxford Oxford University Press. H. Kettenmann, B. Ransom (Eds.).
108. Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011, 134:3602-3615.
109. Mehta V, Pei W, Yang G, et al. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013, 8:e57573.
110. Pitt D, Boster A, Pei W, et al. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 2010, 67:812-818.
111. Stahnke T, Stadelmann C, Netzler A, Brück W, Richter-Landsberg C Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci 2007, 32:25-37.
112. van Horssen J, Schreibelt G, Bö L, et al. NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic Biol Med 2006, 41:311-317.
113. van Horssen J, Schreibelt G, Drexhage J, et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008, 45:1729-1737.
114. McMahon JM, McQuaid S, Reynolds R, FitzGerald UF Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler 2012, 18:1437-1447.
115. Veto S, Acs P, Bauer J, et al. Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain 2010, 133:822-834.
116. Kornek B, Storch MK, Bauer J, et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001, 124:1114-1124.
117. Werner P, Pitt D, Raine CS Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001, 50:169-180.